Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + cixutumumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cetuximab + cixutumumab is a combination of two monoclonal antibodies used in clinical trials for cancer therapy. Cetuximab targets the epidermal growth factor receptor (EGFR), blocking ligand binding and inhibiting downstream signaling pathways involved in cell proliferation, survival, angiogenesis, and metastasis. Cixutumumab targets the insulin-like growth factor-1 receptor (IGF-1R), preventing its activation by endogenous ligands and thereby inhibiting IGF-1R-mediated tumor cell growth and survival. This combination has been investigated primarily in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and advanced non-small cell lung cancer (NSCLC). Clinical studies have not demonstrated significant efficacy or improved outcomes compared to standard therapies; some trials were terminated early due to lack of benefit or safety concerns[1][2][7].
- Other names
- cixutumumab + cetuximab
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on cetuximab + cixutumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + cixutumumab.